Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

PHASE3CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

December 31, 2009

Conditions
Neurogenic Urinary Bladder
Interventions
DRUG

Alfuzosin

"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"

DRUG

Placebo

"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"

Trial Locations (18)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Sofia

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Tallinn

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Kuala Lumpur

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Aministrative Office, Moscow

Sanofi-Aventis Administrative Office, Belgrade

Sanofi-Aventis Administrative Office, Singapore

Sanofi-Aventis Administrative Office, Bratislava

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Taipei

Sanofi-Aventis Administrative Office, Istanbul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY